锯叶棕果实提取物对以LUTS为主要症状的ⅢA型前列腺炎治疗的疗效观察

Saw palmetto fruit extract improves LUTS in type ⅢA prostatitis patients

目的:探讨锯叶棕果实提取物对以下尿路症状(LUTS)为主要症状的ⅢA型前列腺炎治疗的临床疗效。方法:对2015年1月至12月就诊的54例ⅢA型前列腺炎患者予以锯叶棕果实提取物软胶囊口服320 mg/次,1次/d,12周后评价疗效。使用慢性前列腺炎症状指数(NIH-CPSI)评分、排尿日记及国际前列腺症状(IPSS)评分评估治疗前后症状,并行尿动力学检查,比较患者治疗前后变化。结果:治疗12周后,患者的NIH-CPSI评分(18.6±5.34)较治疗前(27.61±3.76)明显下降(P<0.01)、IPSS评分(10.96±4.62)较治疗前(20.44±4.51)有明显下降(P<0.01)。尿动力学检查指标反应治疗前平均尿流率[AFR(8.05±1.42)ml/s]、最大尿流率[MFR(14.22±1.74)ml/s]、残余尿[RU(46.15±16.57)ml]、尿道最大闭合压[MCP(76.52±3.53)cm H2O],治疗后指标[AFR(12.05±2.60)ml/s、MFR(21.32±4.51)ml/s、RU(14.55±10.21)ml、MCP(65.32±4.75)cm H2O]均明显改善(P<0.01)。排尿日记显示治疗后平均排尿量[(285.93±58.68)ml]、排尿次数(8.96±2.50)及夜尿次数(3.15±1.90)次均较治疗前[(124.63±40.55)ml、16.96±4.17、8.94±3.23]明显改善(P<0.01)。治疗期间所有患者均未诉不良反应。结论:锯叶棕果实提取物可有效地改善ⅢA型前列腺炎患者出现的LUTS,提高患者生活质量,且安全性高,可作为临床治疗方案之一。

Objective： To assess the clinical efficacy of the saw palmetto fruit extract （SPFE） in the treatment of lower urinary tract symptoms （LUTS） in patients with type ⅢA prostatitis. Methods ： This retrospective study included 54 cases of type ⅢA pros- tatitis treated in the Outpatient Department of our hospital from January to December 2015. The patients were aged 35.06 ± 5.85 years, with a mean disease course of 3.8 ± 2.1 years, and all received oral medication of SPFE Capsules at the dose of 320 mg qd for 12 weeks. We assessed the therapeutic effects by comparing the NIH-chronic prostatltis symptom indexes （NIH-CPSI） , voiding diary, International Prostate Symptom Scores （IPSS） , and results of urodynamic examination before and after treatment. Results ： Compared with the baseline, both NIH-CPSI and IPSS were significantly decreased after medication （27.61 ± 3.76 vs 18.6 ± 5.34, P 〈 0.01 ; 20.44 ± 4.51 vs 10.96 ±4.62, P 〈 0.01 ） , and urodynamic examination and voiding diary showed dramatic post-medication improvement in the average urinary flow rate （ [ 8.05 ±1.42 ] vs [ 12.05 ± 2.60 ] m]/s, P 〈 0.01 ）, maximum urinary flow rate（[14.22±1.74] vs [21.32±4.51] ml/s, P 〈0.01）, residual urine volume （[46.15 ±16.57] vs [14.55 ±10.21] ml, P 〈 0.01）, maximum urethral closure pressure （[76.52 ±3.53] vs [65.32 ±4.75] cm H20, P 〈0.01）, mean urinary volume （[124.63 ±40.55] vs [285.93±58.681 ml, P 〈0.01）, urination frequency （16.96 ±4. 17 vs 8.96 ±2.50, P 〈0.01）, and nocturia frequency （8.94 ± 3.23 vs 3.15 ±1.90, P 〈 0.01 ）. No apparent adverse reactions were observed in any of the patients. Conclusion SPFE Capsules can safely and effectively improve LUTS and thus the quality of life of patients with type ⅢA prostatitis.